Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of zygomycosis (also known as mucormycosis), a life-threatening fungal infection. Basilea announced on May 28, 2013 that the FDA granted isavuconazole orphan drug designation for the treatment of invasive aspergillosis.
Help employers find you! Check out all the jobs and post your resume.
